Cellectar Biosciences(CLRB) - 2023 Q4 - Annual Results

FLORHAM PARK, N.J., Mar. 27, 2024 – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update. Fourth Quarter and Recent Corporate Highlights · Reported a Complete Remission rate of 64% and Overall Response Rate of 73% in highly refractory patients in an Investigator Initiat ...